Levy L, Bourdais J, Mouhieddine B, Benlot C, Villares S, Cohen P, Peillon F, Joubert D
INSERM U223, Faculté de Médecine Pitié-Salpêtrière, Paris, France.
J Clin Endocrinol Metab. 1993 Jan;76(1):85-90. doi: 10.1210/jcem.76.1.8093621.
Normal and tumoral human pituitaries release in vitro SRIH and contain messenger RNAs encoding preproSRIH. In the present study, we document the presence and characterization of the SRIH precursor in both human normal pituitaries and in GH-secreting adenomas. Molecular sieve filtration of normal pituitary and adenoma acid extracts revealed the presence of three immunoreactive SRIH peaks, distinct from SRIH 1-28 and SRIH 1-14. Western blot analysis performed under both nonreducing and reducing conditions confirmed the presence of the three different immunoreactive forms with respective molecular masses estimated as 21, 17, and 12 kilodaltons. When analyzed in reverse phase high performance liquid chromatography, the three immunoreactive SRIH material contained in the three peaks coeluted with the proSRIH extracted from rat hypothalamus and from a neuroblastoma cell line (N2A) transfected with the human preproSRIH complementary DNA. None of these three forms could bind concanavalin A. Digestion of the three forms with a specific endopeptidase resulted in the generation of SRIH 1-14, indicating that they can be considered as SRIH precursor or related forms. Estimation of proSRIH amount after molecular sieve filtration indicated that normal human pituitaries (n = 4) contained proSRIH in variable amounts (from 26.5-303 pg/mg proteins), the 21-, 17-, and 12-kilodalton forms being always present, in addition to SRIH 1-28. In contrast, among the 21 adenomas tested, only 11 contained proSRIH material (from 9-4480 pg/mg proteins). Moreover, neither SRIH 1-28 nor SRIH 1-14 could be detected in these adenomas. These data demonstrate the presence of high molecular mass SRIH in normal pituitaries which represent unprocessed proSRIH material. This provides an additional argument for a local synthesis of SRIH. Additionally, the fact that only 50% of GH-secreting pituitary adenomas here studied contain exclusively proSRIH may reflect an alteration in messenger RNA translation or in proSRIH processing, or both, resulting in the absence of mature SRIH in these adenomas.
正常和肿瘤性人类垂体在体外释放生长抑素(SRIH),并含有编码前生长抑素原(preproSRIH)的信使核糖核酸。在本研究中,我们记录了人类正常垂体和生长激素分泌型腺瘤中SRIH前体的存在及特征。对正常垂体和腺瘤的酸性提取物进行分子筛过滤,发现存在三个免疫反应性SRIH峰,与SRIH 1-28和SRIH 1-14不同。在非还原和还原条件下进行的蛋白质印迹分析证实存在三种不同的免疫反应形式,各自的分子量估计为21、17和12千道尔顿。在反相高效液相色谱分析中,三个峰中包含的三种免疫反应性SRIH物质与从大鼠下丘脑和转染了人类前生长抑素原互补DNA的神经母细胞瘤细胞系(N2A)中提取的前生长抑素(proSRIH)共洗脱。这三种形式均不能与伴刀豆球蛋白A结合。用特异性内肽酶消化这三种形式会产生SRIH 1-14,表明它们可被视为SRIH前体或相关形式。分子筛过滤后对前生长抑素量的估计表明,正常人类垂体(n = 4)中前生长抑素含量各不相同(从26.5 - 303 pg/mg蛋白质),除了SRIH 1-28外,21-、17-和12-千道尔顿形式总是存在。相比之下,在所测试的21个腺瘤中,只有11个含有前生长抑素物质(从9 - 4480 pg/mg蛋白质)。此外,在这些腺瘤中未检测到SRIH 1-28和SRIH 1-14。这些数据证明正常垂体中存在高分子量SRIH,代表未加工的前生长抑素物质。这为SRIH的局部合成提供了额外的证据。此外,此处研究的仅50%的生长激素分泌型垂体腺瘤仅含有前生长抑素这一事实,可能反映了信使核糖核酸翻译或前生长抑素加工过程中的改变,或两者皆有,导致这些腺瘤中缺乏成熟的SRIH。